-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
2019 IASLC Best of the World Lung Cancer Conference Results in New Virtual Collaboration
Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that the IASLC-LATAM (Latin American) Group organized a BWLCC in Lima. More than 160 attendees were provided with the most scientifically important presentations from the IASLC…
-
What Can We Offer a Patient with a Malignant Mesothelioma?
By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to available therapies for malignant pleural mesothelioma (MPM). Luckily, a renewed interest in MPM with emphasis on immunotherapy has led to several phase II and III…
-
IASLC 2019 Mesothelioma Meeting Offers Innovative Approach for Rapid Learning
Posted: May 27, 2019 Mesothelioma is a rare tumor with limited treatment options. The upcoming IASLC 2019 Mesothelioma Meeting (July 10-12) in New York City—a first of its kind for this disease site—promises to provide the latest clinical trial and emerging therapy information in the field. Preclinical and early clinical trial data will be presented for…
-
The IASLC and the International Thoracic Oncology Nursing Forum: Celebrating Collaboration
By Marianne Davies, DNP, RN, ACNP Posted: May 27, 2019 The International Thoracic Oncology Nursing Forum (ITONF) is an independent organization to support nurses who work in lung cancer and mesothelioma care. The organization started with a collaboration between nurse representatives from the National Lung Cancer Forum for Nurses, in the United Kingdom, and the Australia…
-
IASLC Targeted Therapies of Lung Cancer Meeting Draws Record Abstract Submissions, Attendance
By Paul A. Bunn, Jr., MD, FASCO Posted: May 27, 2019 The 19th annual IASLC Targeted Therapies of Lung Cancer Meeting was held in Santa Monica, California, from February 20 to 23, 2019. The meeting chairs, Roy S. Herbst MD, PhD; Leora Horn, MD, MSc; Suresh S. Ramalingam, MD; and I created a program to be…
-
Checkpoint Inhibitors and Clinical Decision Making: A Q&A with Dr. Nasser H. Hanna
Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes in the study and management of all forms of lung cancer. Dr. Hanna spoke with the IASLC Lung Cancer News in detail about the questions—…
-
Lorlatinib’s Role in ROS1-Positive Lung Cancer
By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. Food and Drug Administration for the treatment of advanced ALKpositive lung cancer. The approval represents a significant advance for patients with ALK-positive lung cancer. Given…
-
Howard (Jack) West, MD
Posted: May 27, 2019 Howard (Jack) West, MD, has moved from the Swedish Cancer Institute in Seattle, where he directed the medical oncology component of thoracic oncology program, to City of Hope, Duarte, Calif, in March 2019. Dr. West, an associate clinical professor of medical oncology and executive director of Employer Services, made the move to…
-
FDA’s New Acting Commissioner
Posted: May 27, 2019 After Scott Gottlieb’s resignation as commissioner of the U.S. Food and Drug Administration (FDA) in early March, the Secretary of Health and Human Services Alex M. Azar II appointed Norman E. Sharpless, MD, as acting commissioner. Dr. Sharpless, a physician–scientist, is currently the director of the National Cancer Institute. In a statement,…
-
Charles B. Simone, II, MD
Posted: May 27, 2019 Charles B. Simone, II, MD, has joined the New York Proton Center, which is opening this spring, as its chief medical officer. In his previous position, Dr. Simone was the medical director of the Maryland Proton Treatment Center and an associate professor of radiation oncology at the University of Maryland School of…